StonvexLoading…
StonvexStonvexStonvexCore line items from GSK's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | £32.67B | £31.38B | £30.33B | £29.32B |
Operating Income | £7.93B | £4.02B | £6.75B | £6.43B |
Net Income | £6.29B | £2.95B | £5.31B | £15.62B |
EPS (Diluted) | £1.39 | £0.62 | £1.20 | £3.66 |
Total Assets | £61.12B | £59.46B | £59.01B | £60.15B |
Total Liabilities | £45.16B | £46.38B | £46.21B | £50.05B |
Cash & Equivalents | £3.40B | £3.87B | £2.94B | £3.72B |
Free Cash Flow OCF − CapEx | £6.39B | £5.16B | £5.45B | £6.26B |
Shares Outstanding | Not available | Not available | Not available | Not available |